0.1950GBp0.00%Mkt Cap: 1.45M GBpP/E: —Last update: 2026-06-01
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II tri…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.45M GBp
Enterprise Value-222.04K GBp
Revenue (TTM)49.77K GBp
Gross Profit49.77K GBp
Net Income (TTM)-1.92M GBp
Revenue/Share0.0000 GBp
Last Price0.1950 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees14
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.13
EV/Revenue-4.46
P/S29.10
P/B0.22
EPS (TTM)-0.01
EPS (Forward)-1.86
52W Range
0.18002% of range0.8750
52W High0.8750 GBp
52W Low0.1800 GBp
Profitability
Gross Margin100.00%
Oper. Margin-4053.35%
EBITDA Margin0.00%
Profit Margin-3848.71%
ROE-44.37%
ROA-44.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.58M GBp
CapEx (TTM)38.16K GBp
FCF Margin-2147.28%
FCF Yield-73.79%
Net Debt-512.13K GBp
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.00
Current Ratio9.66
Quick Ratio8.87
Book Value/Sh0.0090 GBp
Cash/Share0.0010 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateApr 6, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.742.80M
Float336.70M
Insiders11.68%
Institutions0.00%
Technical
SMA 500.2709 (-28.0%)
SMA 2000.3795 (-48.6%)
Beta-0.56
S&P 52W Chg27.94%
Avg Vol (30d)15.91M
Avg Vol (10d)28.51M
Technical Indicators
RSI (14)22.4
MACD-0.0253
MACD Signal-0.0237
MACD Hist.-0.0016
BB Upper0.3076 GBp
BB Middle0.2313 GBp
BB Lower0.1550 GBp
BB Width65.99%
ATR (14)0.0232 GBp
Vol Ratio (20d)0.14x